Clinical Improvement by Vildagliptin/Metformin (Equmet) For Diabetic Patient with Remarkable Arteriosclerosis from Slight HbA1c Elevation for Years

Arakawa T, Bando H, Ogawa H, Nagahiro S, Nakanishi M and Watanabe O

Published on: 2023-07-11

Abstract

This case is 73-year-old male surgeon with light degree of type 2 diabetes (T2D) for 10 years. The HbA1c was under 7.0% until 2020, and became more than 7% after 2021 without oral hypoglycemic agents (OHAs). He was provided vildagliptin/metformin (EquMet) from March 2023, and HbA1c decreased from 7.2% to 6.2% for 3 months, indicating clinical effect. For the exam of arterial stiffness, brachial-ankle pulse wave velocity (baPWV) showed 2151/2154 in right/ left artery, respectively. It revealed +2SD of the standard level for 73 years old, suggesting that highly-developed arteriosclerosis would be from prolonged diabetic glycemic variability for years.